地拉罗司是治疗什么病症的呢？

It is a tridentate iron chelator that combines with ferric iron ions at a ratio of 2:1 to form a complex, which is excreted in the feces, thereby reducing iron storage in the body. Deferasirox (DFS, ICL670), deferasirox is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for deferasirox for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT). Today let’s take a look at what diseases deferasirox treats?

Deferasirox Indications: 1. Patients with chronic iron overload transfusion hemosiderinosis secondary to blood transfusion who are 2 years old or older will have symptoms of chronic iron overload when serum ferritin continues to be >1000 L, and iron chelation therapy should be started at this time. 2. Iron chelators can also be given to patients undergoing ASCT treatment when iron overload occurs; 3. It can be used to treat reversible renal insufficiency caused by Fanconi syndrome.

In terms of dosage: the common starting dose of deferasirox is 20 mg/(kg·d). If there is a large amount of blood transfusion and the iron increase is >0.5 mg/(kg·d) or the iron load before treatment is high, the recommended dose is 30 mg/(kg·d). If the iron increase is <0.3 mg/kg, 10-15 mg/kg/d is enough to control the condition. Administer on an empty stomach 30 minutes before meals and should be completely dissolved in water or apple or orange juice. Lower doses of deferasirox [5-10 mg/(kg·d)] can only be used in young patients with mild iron overload and few blood transfusions, or in elderly patients who have not received satisfactory results from chelation therapy in the past; patients using deferasirox 20 and 30 mg/(kg·d) need to carefully monitor body iron stores, because body iron levels may continue to rise in 50% and 10% of patients. In addition, the frequency of blood transfusion can also affect the effect of deferasirox in controlling liver concentration. When the iron intake is greater than 0.5 mg/(kg·d), only 47% of patients who receive the same dose of deferasirox have a reduction in liver concentration.

The above is the content of the indications, I hope it can help you!